Plozasiran and Apolipoprotein C-III Inhibition: Lipoprotein Particle Insights and Cardiovascular Implications
- PMID: 40368574
- DOI: 10.1016/j.jacc.2025.03.519
Plozasiran and Apolipoprotein C-III Inhibition: Lipoprotein Particle Insights and Cardiovascular Implications
Keywords: apolipoprotein C-III; cardiovascular risk; nuclear magnetic resonance spectroscopy; plozasiran; triglyceride.
Conflict of interest statement
Funding Support and Author Disclosures Dr Schwartz has received research support from the Cooperative Studies Program of the U.S. Department of Veterans Affairs; and to the University of Colorado from AstraZeneca, Sanofi, and Silence Therapeutics. Dr Cobbaert has had research collaboration with Roche Diagnostics.
Publication types
LinkOut - more resources
Full Text Sources
